NEW YORK (TheStreet) -- Achillion Pharmaceuticals  (ACHN) - Get Report touched another 52-week high of $12 on Tuesday after UBS tabbed the company as a possible takeover target on Monday in the wake of Roche's $8.3 billion bid for InterMune (ITMN) .

The deal led the biotech sector up on Monday and UBS highlighted Achillion as another potential merger and acquisition target.

"While we had viewed InterMune as a top take-out candidate in biotech, we also note our Buy rating on Achillion Pharmaceuticals shares also reflects M&A potential," the firm wrote, according to Barron's.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was up 4.64% to $11.28 at 12:09 p.m. More than 8.9 million shares had changed hands, compared to the average volume of 7,668,470.

Image placeholder title

ACHN

data by

YCharts

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.